The AtriCure Inc. (ATRC) Stock Rating Reaffirmed by Piper Jaffray Companies

The AtriCure Inc. (ATRC) Stock Rating Reaffirmed by Piper Jaffray Companies

Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded AtriCure from a hold rating to a buy rating and set a $26.00 price objective on the stock in a report on Tuesday, May 9th. Needham & Company LLC restated a buy rating and set a $25.00 price objective (up previously from $23.00) on shares of AtriCure in a report on Friday, May 5th. Canaccord Genuity restated a buy rating and set a $22.00 price objective on shares of AtriCure in a report on Monday, April 17th. Northland Securities restated a buy rating and set a $24.00 price objective on shares of AtriCure in a report on Monday, March 20th. Finally, TheStreet upgraded AtriCure from a d+ rating to a c- rating in a report on Monday, May 15th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. AtriCure currently has a consensus rating of Buy and a consensus price target of $23.25.

Piper Jaffray Companies reaffirmed their overweight rating on shares of AtriCure Inc. (NASDAQ:ATRC) in a report published on Tuesday morning. They currently have a $26.00 target price on the medical device company’s stock.

Shares of AtriCure (ATRC) opened at 21.43 on Tuesday. The stock has a 50 day moving average price of $21.08 and a 200-day moving average price of $18.84. AtriCure has a 52 week low of $13.45 and a 52 week high of $23.95. The firm’s market capitalization is $727.46 million.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, May 4th. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01. AtriCure had a negative return on equity of 19.84% and a negative net margin of 23.78%. The business had revenue of $41.30 million for the quarter, compared to analysts’ expectations of $40.25 million. During the same quarter last year, the firm earned ($0.31) earnings per share. The business’s revenue was up 15.0% on a year-over-year basis. On average, analysts anticipate that AtriCure will post ($0.96) EPS for the current year.

In other AtriCure news, Director Elizabeth D. Krell sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $21.44, for a total value of $214,400.00. Following the transaction, the director now directly owns 24,162 shares of the company’s stock, valued at $518,033.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Andrew L. Lux sold 20,000 shares of the firm’s stock in a transaction dated Friday, March 17th. The shares were sold at an average price of $18.85, for a total value of $377,000.00. Following the completion of the transaction, the senior vice president now directly owns 85,589 shares in the company, valued at $1,613,352.65. The disclosure for this sale can be found here. Company insiders own 10.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Peregrine Capital Management LLC increased its stake in shares of AtriCure by 10.2% in the first quarter. Peregrine Capital Management LLC now owns 994,591 shares of the medical device company’s stock valued at $18,808,000 after buying an additional 92,071 shares in the last quarter. Teachers Advisors LLC increased its stake in shares of AtriCure by 2.2% in the fourth quarter. Teachers Advisors LLC now owns 71,668 shares of the medical device company’s stock valued at $1,403,000 after buying an additional 1,520 shares in the last quarter. First Light Asset Management LLC increased its stake in shares of AtriCure by 1.0% in the fourth quarter. First Light Asset Management LLC now owns 939,012 shares of the medical device company’s stock valued at $18,376,000 after buying an additional 9,136 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in shares of AtriCure during the fourth quarter valued at $1,847,000. Finally, Tudor Investment Corp Et Al acquired a new stake in shares of AtriCure during the fourth quarter valued at $253,000. 79.30% of the stock is currently owned by institutional investors. AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ATRC”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment